To hear about similar clinical trials, please enter your email below
Trial Title:
The Value of MRI in Assessing the Status of Retroperitoneal Resection Margin in Colon Cancer
NCT ID:
NCT05859581
Condition:
Colon Cancer
Conditions: Official terms:
Colonic Neoplasms
Conditions: Keywords:
Colon cancer
MRI
Resection margin
Study type:
Interventional
Study phase:
N/A
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Diagnostic
Masking:
None (Open Label)
Intervention:
Intervention type:
Procedure
Intervention name:
Beyond complete mesocolic excision surgery
Description:
If the participants were diagnosed with positive retroperitoneal resection margin (RPRM),
they underwent beyond complete mesocolic excision surgery to ensure the R0 resection.
Arm group label:
Suspected positive RPRM on MRI
Summary:
The goal of this clinical trial is to explore the value of colon MRI in assessing the
status of retroperitoneal resection margin (RPRM) for advanced colon cancer.
The main questions it aims to answer are:
- Concordance between MRI suspected RPRM positive and pathologically confirmed
positive.
- Can RPRM-positive patients undergo beyond complete mesocolic excision (CME) surgery
in order to achieve R0 resection?
Participants will undergo colon MRI examination and once MRI suspects RPRM positive, they
will receive beyond CME surgery.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- primary colon adenocarcinoma confirmed by biopsy
- preoperative CT suspecting retroperitoneal resection margin (RPRM) positive
- received colon MRI scan
- underwent beyond complete mesocolic excision surgery
- sufficient clinical and pathological results
Exclusion Criteria:
- combined with other malignant tumors
- simultaneous distant metastasis
- definite invaded other organs or structures (T4b tumors)
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Beijing Cancer Hospital
Address:
City:
Beijing
Zip:
100142
Country:
China
Status:
Recruiting
Contact:
Last name:
Zhen Guan, MD
Phone:
861088196825
Email:
18801231091@163.com
Start date:
April 2, 2023
Completion date:
August 31, 2023
Lead sponsor:
Agency:
Peking University Cancer Hospital & Institute
Agency class:
Other
Source:
Peking University Cancer Hospital & Institute
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05859581
